ArticleCancer chemotherapy and pharmacology2023

Comparative biochemical kinase activity analysis identifies rivoceranib as a highly selective VEGFR2 inhibitor.

Seong Jang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.